Drug Trial Radar · NCT05583474
OPC-1085EL in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Chinese Subjects
Last checked: Nov 20, 2026Latest source record: Mar 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
204
Actual
Start
Sep 27, 2022
Primary completion
Nov 22, 2024
Study completion Dec 26, 2024
Sponsor
- Lead sponsor
- Otsuka Beijing Research InstituteOtsuka
- Sponsor type
- Industry
- First posted
- Oct 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
It is a phase III, multi-center, randomized, single-blind (to evaluator), parallel, and positive-controlled clinical trial evaluating the efficacy and safety of OPC-1085EL in the treatment of primary open angle glaucoma or ocular hypertension in Chinese subjects. It is planned that 240 subjects (120 in each group) will be randomly assigned to receive OPC-1085EL or 0.005% latanoprost ophthalmic solution (latanoprost) at a ratio of 1:1.
Conditions
- Open Angle Glaucoma or Ocular Hypertension
Interventions
OPC-1085ELDrug
one drop for each eye, once per day
0.005% LatanoprostDrug
one drop for each eye, once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- evaluate pre-dose intraocular pressure change from baseline to week 8Time frame: baseline;week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eye & ENT Hospital of Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.